Angiogenesis has always been the topic of major scientific interest in the field of malignant
tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by …

Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody that may
prolong survival in ovarian and cervical cancer when given in combination with …

The limitations of current anti-angiogenic therapies necessitate other targets with
complimentary mechanisms. Here, we show for the first time that soluble E-cadherin (sE …

Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer
(EOC), thus establishing this receptor as a candidate target for the development of novel …

Background Ovarian cancer (OC) is a prevalent malignancy in the female reproductive
system, and developing effective targeted therapies for this disease remains challenging …

Despite the recent advances in the treatment of ovarian cancer, it remains an area of high
unmet medical need. Epithelial ovarian cancer is associated with high levels of mesothelin …

High-grade serous ovarian cancer (HGSOC) has the highest mortality rate among all
gynecological cancers. Patients are generally diagnosed in an advanced stage with the …

Despite frequent initial response rates of epithelial ovarian cancer to platinum-based
chemotherapy the majority of patients develop drug resistance. Our aim was to evaluate …

Oesophageal adenocarcinoma (OAC) is a disease with an incredibly poor survival rate and
a complex makeup. The growth and spread of OAC tumours are profoundly influenced by …

Angiogenesis inhibitors have clearly shown activity in ovarian cancer in various settings;
however, preliminary data did not reflect significant survival benefit. Bevacizumab has been …